Institution: KCMC-Duke University collaboration
Kilimanjaro Christian Medical Centre (KCMC)
Moshi, Tanzania
http://www.kcmc.ac.tz

Contact: Oresto Michael Munisi
Study Coordinator
godhappyus@yahoo.com

LAB RESOURCES

Please describe the laboratory facilities available in your research institute, including the items listed below (if applicable):

- **Lab space and equipment (general):** Cell Dyne3500/3700, Cobas Integra400 (2), Elx800(Reader), Elx50(washer)
- **BSL-2 lab space and equipment:** No
- **BSL-3 lab space and equipment:** facscaliber, facscount
- **Flow cytometry equipment:** facscaliber, facscount
- **Other:**
  - HIV RNA PCR, M200 op/rt Abbott, GenProb (M.avium, M.Tb), BactAlert (blood system for TB and blood cultures), Fluorescent microscope (TB), BD Mgt (liquid sputum culture for TB), Microscopes (smear review)

Please list the research groups in your institute, including the size and areas of expertise for each group:

- ACTG
- Adult HIV IMPAACT
- Pediatric HIV

BIOLOGICAL SPECIMEN REPOSITORY

Please describe the biological specimens stored at your institute:

- Plasma
- Dried blood spot (DBS)
- Serum

Does your institute have a database of stored samples: Yes
Please provide details on methods for biological specimen storage at your institute (e.g., are Standardized Operating Procedures used?):

- SOP’s are used. Site uses LDMS (lab data management system) where each specimen is given a global ID # unique to the site.

Please describe the equipment/facilities available for sample storage at your institute, including items listed below (if applicable):

- **-80C freezers**
  - 2 Nuaire

- **Nitrogen storage tanks**
  - 2

- **Dry ice availability**
  - Order from World Courrier in Dar es Salaam (48 hour notice)

- **Use of a nitrogen generator**
  - Main Hospital KCMC makes liquid nitrogen

- **Other**
  - Site has a generator

### TRAINING AND EDUCATION

Please describe the training initiatives your institution has in place for individuals prior to working in clinical studies?

- MTS (medical training solutions)
- CITI (ethical modules) program
- GCP (good clinical practice) training

Please describe the training initiatives your institution has in place for individuals prior to working in the laboratory?

- MTS (medical training solutions)
- CITI (ethical modules) program
- GCP (good clinical practice) training

What assays/techniques do you excel in at your institute?

- Medical Doctor who oversees the clinical care of the study patients, study data safety and management, research and publication of research results.
What training could you provide to visiting scientists?

- “Hands-on” research experience by letting them participate directly in various research projects which are ongoing or new to the site.

What rank are the majority of your trainees? (e.g., approximate numbers of undergraduate students, Masters, PhD, post-doc, MDs)

- Undergraduates and Masters

Does your institute receive funds to support training initiatives? Yes

Please provide details about the funds your institute receive to support training initiatives.

- From NIH through programs like AITRP, HIV associated malignancy training fund and Medical Education Partnership Initiative (MEPI)

Does your institution send trainees abroad for additional training? Yes

Please indicate the number of trainees sent abroad per year, the source of funding, the location of training, and the type of training received.

- Varies each year depending on available funds and quality of applicants. We have long (years) and short (months) term programs

What Masters and/or Doctoral programs does your institution offer? None

COLLABORATIONS

Please list and briefly describe your current collaboration with any African institutions for either research or training purposes.

- The “Medical Education Partnership Initiative” collaborates with the Tumaini University in Tanzania.

Please list and briefly describe your institution’s collaborations and/or partnerships with entities outside of Africa (e.g., organizations and networks in the USA, Europe, etc. – including CFARS, NIH clinical trials networks, HPTN, HVTN, AMC, leDEA, USAID, PEPFAR, etc.)

- IMPAACT
- ACTG
- IVI (International Vaccine Initiative)
CLINICAL COHORTS

Do you have access to existing clinical cohorts in Africa or USA? Yes

Please describe each existing clinical cohort that you have access to, including specifics like “HIV-TB infected HAART naïve adults”, sample size, sample type, sex, age, and whether clinical samples are currently being collected and/or stored (specify which samples).

- A5207: Comparison of 3 strategies given for 7 and 21 days to reduce emergence of resistance of nevirapine resistance HIV-1 following a single intrapartum dose of nevirapine.
- A5230: Study of lopinavir/ritonavir in participants experiencing virologic relapse.

Are you planning to establish any new clinical cohorts over the next 5 years? Yes

Please describe the clinical cohorts that you are planning to establish, including specifics such as “HIV-TB infected HAART naïve adults”, sample type, sex, and age.

- (HiFLAC)” A5273: “Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT).

DATA MANAGEMENT

Please describe the DATA MANAGEMENT FACILITIES available in research institute, including the items listed below (if applicable):

*Data management expertise, including staff complement (general):* 3 trained personnel are available

*On-site database design, implementation and trouble-shooting:* A system is available

*Details of off-site support (by whom):* DSMB (data safety management board)